PRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY, on Thursday, September 5, 2024, at 10:00 a.m. ET Cantor Global Healthcare Conference 2024 in New York, NY on Tuesday, September 17, 2024, at 1:55 p.m. ET A live audio webcast of each presentation can also be accessed via the i ...

Amicus Therapeutics, Inc.'s (FOLD) lead marketed drug, Galafold (migalastat), is the first and only approved oral medicine for patients living with Fabry disease, having amenable genetic variants. The drug has witnessed a strong sales uptake driven by continued demand. Sales of Galafold have been rising consistently over the past years. In the first six months of 2024, the drug generated sales worth $210.2 million, which increased 17% year over year at a constant currency basis. Galafold is currently approv ...

NicoElNino/iStock via Getty Images Amicus Therapeutics, Inc. (NASDAQ:FOLD) focuses on rare and orphan diseases, particularly Fabry and Pompe. The company's portfolio includes Galafold and Pombiliti. Notably, Galafold is an oral treatment that seems effective for Fabry by stabilizing the dysfunctional enzyme alpha-Gal A. FOLD's Pombiliti is a combination therapy with Opfolda, indicated for Pompe disease. Pombiliti replaces and stabilizes deficient or dysfunctional GAA enzymes needed for glycogen breakdown, h ...

Amicus Therapeutics (FOLD) reported second-quarter 2024 adjusted earnings of 6 cents per share, beating the Zacks Consensus Estimate of 3 cents. The company had incurred a loss of 7 cents per share in the year-ago quarter. Please note that the company achieved non-GAAP profitability for the first time in the reported quarter. The year-over-year improvement can be attributed to higher revenues from Galafold (migalastat) sales and incremental revenues from the sale of the newly approved combo drug, Pombiliti ...

| --- | --- | --- | --- | |--------------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES | | | | | 2Q24 Results Conference Call & Webcast | | | | | August 8, 2024 | | | | | | | | | 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product can ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President and CEO Sebastien Martel - Chief Business Officer Dr. Jeff Castelli - Chief Development Officer Simon Harford - Chief Financial Officer Dr. Mitchell Goldman - Chief Medical Officer Ellen Rosenberg - Chief Legal Officer Conference Call Participants Tazeen Ahmad - BofA Securities Ellie Merle - UBS Anupam Rama - ...

Amicus Therapeutics (FOLD) reported $126.67 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 34%. EPS of $0.06 for the same period compares to -$0.15 a year ago. The reported revenue represents a surprise of +4.90% over the Zacks Consensus Estimate of $120.76 million. With the consensus EPS estimate being $0.03, the EPS surprise was +100.00%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share FOLD NASDAQ Global Market (Mark One) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHA ...

Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.06 per share when it actually produced a loss of $0.02, delivering a surprise of 66.67%. Over the last four quarters, t ...

Exhibit 99.1 Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates Q2 2024 Total Revenue of $126.7M, a 34% Increase Year-over-Year GalafoldQ2 Revenue of $110.8M, up 17% Year-over-Year Pombiliti + OpfoldaQ2 Revenue of $15.9M, up 44% from Q1 2024 Raising 2024 Total Revenue Growth Guidance to 26%-31% at CER and 2024 Galafold Growth Guidance to 14%-18% at CER Narrowing non-GAAP Operating Expense Guidance to $345M to $360M Non-GAAP Profitability Achieved in Q2 and H1 2024 with ...